Evidence map›Paper›PMID 26654719›Full record

ReviewThrombosis research2016

The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs.

Scott D Grosse, Richard E Nelson, Kwame A Nyarko, Lisa C Richardson, Gary E Raskob

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Thrombosis research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06652568 (Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection), which is not on this map. Cited by 205 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06652568 nacompletednot on this mapstarted 2023, after this paper: background citation

Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection

TypeinterventionalSponsorThinkSono, Ltd.Ran2023 to 2025Enrolled634ConditionsDeep Vein Thrombosis, Deep Vein Thrombosis, Pulmonary EmbolusArmsThinkSono System
3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. The Diagnostic Value of the Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Deep Venous Thrombosis: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Review

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Scott D GrosseNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: sgrosse@cdc.gov.
Richard E NelsonVeterans Affairs Salt Lake City Health Care System, University of Utah Department of Internal Medicine, Salt Lake City, UT, USA.
Kwame A NyarkoNational Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lisa C RichardsonNational Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Gary E RaskobCollege of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is an important cause of preventable mortality and morbidity. In this study, we summarize estimates of per-patient and aggregate medical costs or expenditures attributable to incident VTE in the United States. Per-patient estimates of incremental costs can be calculated as the difference in costs between patients with and without an event after controlling for differences in underlying health status. We identified estimates of the incremental per-patient costs of acute VTEs and VTE-related complications, including recurrent VTE, post-thrombotic syndrome, chronic thromboembolic pulmonary hypertension, and anticoagulation-related adverse drug events. Based on the studies identified, treatment of an acute VTE on average appears to be associated with incremental direct medical costs of $12,000 to $15,000 (2014 US dollars) among first-year survivors, controlling for risk factors. Subsequent complications are conservatively estimated to increase cumulative costs to $18,000-23,000 per incident case. Annual incident VTE events conservatively cost the US healthcare system $7-10 billion each year for 375,000 to 425,000 newly diagnosed, medically treated incident VTE cases. Future studies should track long-term costs for cohorts of people with incident VTE, control for comorbid conditions that have been shown to be associated with VTE, and estimate incremental medical costs for people with VTE who do not survive. The costs associated with treating VTE can be used to assess the potential economic benefit and cost-savings from prevention efforts, although costs will vary among different patient groups.

Indexed as

Cost of IllnessModels, EconomicAgedComputer SimulationCost SavingsHealth Care CostsHumansIncidenceMiddle AgedRisk FactorsSurvival RateUnited StatesVenous Thromboembolism

Identifiers

PMID26654719
PMCPMC4706477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.